Latest News

Various prognostic characteristics have been established in the renal cell carcinoma (RCC). However, the impact of tumor laterality is unknown. The objective of the current study was to explore the predictive and prognostic impact of tumor laterality of RCC after surgery. This investigation was a population-based retrospective cohort study of patients with RCC from the […]

Abnormal expressions of long noncoding RNAs (lncRNAs) are very common in clear cell renal cell carcinoma (ccRCC), and some of these have been reported to be highly correlated with prognosis of ccRCC patients. “edgeR” AND “DEseq” R packages were used to explore differentially expressed genes (DEGs) between normal and tumor tissues of ccRCC samples from […]

Primary adult renal sarcomas (RSs) are rare aggressive neoplasms. Clinical outcomes are extremely poor, and optimal treatment remains challenging. To identify genomic alterations (GAs) in patients with RSs. Comprehensive genomic profiling (CGP) was conducted on DNA/RNA extracted from formalin-fixed paraffin-embedded tissue using the FoundationOne Heme/Sarcoma assay in 13 adult, locally advanced or metastatic RSs of […]

To develop a machine learning (ML)-assisted model for identifying the candidates for extended pelvic lymph node dissection (ePLND) in prostate cancer by integrating clinical, biopsy and precisely defined MRI findings. 248 patients treated with radical prostatectomy and ePLND or PLND were included. ML-assisted models were developed from 18 integrated features using a logistic regression (LR), […]

To investigate whether presence of multifocality on multi-parametric magnetic resonance imaging (mpMRI) would increase the likelihood of detecting clinically-significant prostate cancer (csPCa) in a PI-RADS 4 lesion. We identified patients with at least one PI-RADS 4 lesion who underwent mpMRI-ultrasound fusion prostate biopsy. Patients were grouped into one of four cohorts – cohort 1 (a […]

Two phase 3 trials, COMET-1 and COMET-2, have reported that cabozantinib did not significantly extend overall survival (OS) compared to prednisone and prednisone plus mitoxantrone, respectively, in post-docetaxel patients with metastatic castration-resistant prostate cancer (mCRPC). We conducted a retrospective analysis of a combined data set from these trials to identify a benefit in subsets of […]

In prostate cancer, it is unknown whether stereotactic body radiation therapy (SBRT) is substituting for other radiation treatments, substituting for surgery, or expanding the pool of patients receiving treatment instead of active surveillance. Using SEER-Medicare, we identified men diagnosed with prostate cancer between 2007 and 2011 and developed physician-hospital networks by identifying each patient’s treating […]

Whether or not adding systematic biopsies (transrectal ultrasound-guided biopsy [TRUS-Bx]) to targeted cores in patients with a lesion detected at multiparametric magnetic resonance imaging (mpMRI) is still a debated topic. To identify patients who can avoid TRUS-Bx at the time of mpMRI targeted biopsy (MRI-TBx) relying on individual patient probability to harbour clinically significant prostate […]

After the publication of the CARMENA findings1 that questioned the survival benefit of cytoreductive nephrectomy in contemporary metastatic renal cell carcinoma patients, the role of cytoreductive nephrectomy has been debated. The concerns about the use of cytoreductive nephrectomy may be even more prominent when considering older patients. Since no contemporary data exists to specifically ascertain […]